ARTIA™ RECONSTRUCTIVE TISSUE MATRIX specifically designed for use in breast plastic and reconstructive surgeries\textsuperscript{1,2}

Allergan’s porcine-derived acellular dermal matrix

Available in rectangular and contour sizes to provide you with more options\textsuperscript{1}
WHAT IS ARTIA™
Reconstructive Tissue Matrix?

- A sterilized, surgical mesh that is derived from porcine skin, and is processed and preserved in a patented aqueous phosphate-buffered solution containing matrix stabilizers²
- A tissue patch designed to reinforce soft tissue where weakness exists, and for the surgical repair of damaged or ruptured soft tissue membranes²
- Provides for a strong and biocompatible implant that will incorporate into the patient’s tissue with associated cell and microvascular ingrowth²

Product characteristics²
- Pre-sterilized²
- Does not require refrigeration—can be stored from -8°C–30°C²
- Ready-to-use out of the package following a 2-minute soak in sterile saline or lactated Ringer’s solution²
- Once opened and retained in sterile solution, must be used within 4 hours²

Perforated options designed to:¹
- Allow fluid to flow through matrix¹
- Support tissue ingrowth¹,3*
- Incorporate a 1.2 cm space around the perimeter of the perforation pattern in each piece to avoid suturing interference¹

Contoured shape options specifically designed for breast reconstruction, and designed to:¹
- Reduce time for product trimming¹
- Make intraoperative placement easier and more predictable¹

Consider Artia™ to reconstruct, recontour and reform human soft connective tissue²

* As demonstrated in a non-human primate abdominal wall model
HOW DOES ARTIA™ COMPARE to other acellular dermal matrices (ADMs)?

Artia™ enables the surgical repair of damaged or ruptured soft tissue membranes in breast plastic and reconstructive applications.

**Material performance**

**Drape**
(ratio of draped area over undraped area)
- Artia™ demonstrated superior drapability than Strattice™ Pliable.
- Artia™ demonstrated statistically similar drapability to AlloDerm™.

**Variability in tissue stretch**
(standard variability in strain)
- Artia™ demonstrated 3x less variation in stretch than AlloDerm™.
- Artia™ demonstrated a higher average strain than Strattice™ Pliable.
- In terms of stretch, Artia™ behaved in a more predictable way than AlloDerm™ RTU.

**Thickness uniformity**
(standard deviation in thickness)
- Artia™ demonstrated a more uniform thickness from piece to piece than AlloDerm™.
- Compared to AlloDerm™, Artia™ demonstrated similar thickness consistency within pieces.

**Out-of-the-package histology**
[hematoxylin and eosin (H&E) staining]
- Artia™ demonstrated similar histological microstructure to AlloDerm™, both of which are structurally similar to human tissue.

Artia™ offered equal or better handling, drapability, and ease of suturing through compared to Strattice™ Pliable and SurgiMend®.

* Based on qualitative evaluation by European surgeons (n=10).
Preclinical results

Artia™ demonstrated superior biologic response to Strattice™ Pliable in the immune-competent-rat-subcutaneous-implant model at both 2 and 4 weeks10

**Inflammatory response** (Monocyte activation)

- **Human monocytes did not activate** in presence of Artia™ in vitro, similar to AlloDerm™11
- Artia™ demonstrated a **minimized immunological response** in vitro11

**Subcutaneous in vivo testing** (Immune-competent rodent, H&E staining)

- Artia™ demonstrated **less inflammatory cell infiltration and greater and more consistent cell repopulation** (fibroblasts) compared to Strattice™12

**Subcutaneous in vivo testing** (non-human primate model)

- The overall **biologic response** of Artia™ was found to be **superior to Strattice™ Pliable**13
- The overall **biologic response** of Artia™ was found to be **equivalent to AlloDerm™**13

Artia™ is the latest addition to the ADM family and offers better biologic response compared to Strattice™ Pliable, as demonstrated in a primate model13

**HOW DOES ARTIA™ COMPARE to other acellular dermal matrices (ADMs)?**
**Clinical results**

In a short-term safety profile evaluating the outcomes following the use of Artia™ in consecutive immediate implant-based breast reconstruction in 17 patients, there were no implant losses (mean follow up of 177 days), compared with over 9% identified in an audit for the Implant Breast Reconstruction evAluation (IBRA) study.

- Artia™ appeared to provide an effective, functional, reconstructive matrix with a generally good safety profile when utilised for either therapeutic or prophylactic mastectomy with implant reconstruction.
- Investigators stated they associated Artia™ with minimal post-operative complications and good patient satisfaction.

Outcome data in patients who had received Artia™-assisted breast reconstruction was compared to patients recipient of other ADMs such as Strattice™ or Surgimend™.

- Artia™ was used in 31 patients undergoing 51 implant-based breast reconstructions between July 2016 and August 2017.
- The overall complication rate was 9.8% with reports of complications in 5 breasts from 4 patients (mean follow-up of 171 days).
  - Minor complications: 3 cases of seromas which were drained in the post-operative clinic appointment.
  - Major complications: 1 patient suffered bilateral implant losses following infection and skin necrosis.
- No delays to adjuvant treatment in therapeutic cases.
- Complication rates compared with those of well-established ADMs such as Strattice™, Surgimend™ and AlloDerm™ from literature.

Artia™ has been demonstrated in breast reconstruction patients to be effective, with a generally good safety profile, and with minimal post-operative complications.
**Artia™ RTM**
Allergan’s porcine-derived acellular dermal matrix for breast reconstruction

<table>
<thead>
<tr>
<th>Product Code</th>
<th>Product Size</th>
<th>Coverage</th>
</tr>
</thead>
<tbody>
<tr>
<td>06161097EU</td>
<td>06161097</td>
<td>6 x 16 cm</td>
</tr>
<tr>
<td>08161097EU</td>
<td>08161097</td>
<td>8 x 16 cm</td>
</tr>
<tr>
<td>10161097EU</td>
<td>10161097</td>
<td>10 x 16 cm</td>
</tr>
<tr>
<td>08201097EU</td>
<td>08201097</td>
<td>8 x 20 cm</td>
</tr>
</tbody>
</table>
**ORDERING INFORMATION**

**Artia™ Contour**
Specifically designed for breast reconstruction

**Artia™ Contour**

<table>
<thead>
<tr>
<th>Product Code</th>
<th>Product Size</th>
<th>Coverage</th>
</tr>
</thead>
<tbody>
<tr>
<td>CS1097EU</td>
<td>Contour Small 14.7 x 7.3 cm</td>
<td>77 cm²</td>
</tr>
<tr>
<td>CM1097EU</td>
<td>Contour Medium 9.6 x 19.3 cm</td>
<td>132 cm²</td>
</tr>
<tr>
<td>CL1097EU</td>
<td>Contour Large 10.7 x 21.5 cm</td>
<td>164 cm²</td>
</tr>
<tr>
<td>CXL1097</td>
<td>Contour X-Large 23.7 x 11.8 cm</td>
<td>200 cm²</td>
</tr>
</tbody>
</table>
ADDITIONAL INFORMATION

Ordering:
To place an order, please call GDM at 040 - 3031090, contact your account manager from GDM or visit www.gdm-medical.nl.

Please refer to the package insert supplied with each device for indications, contraindications, warnings, instructions for use, limited warranty, and patient, physician, and manufacturer information.

Adverse events and reporting:
Potential adverse events are those typically associated with the surgical mesh materials and/or their implantation procedures including, but not limited to, infection, foreign body response, failure to integrate, hematoma, seroma formation, lack of tissue perfusion, wound dehiscence, recurrence of tissue defect, and inflammation. If an unanticipated event occurs, alteration of surgical plan may be necessary at the surgeon’s discretion.²

References:

GDM
a GD Medical Pharma company